GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Not Financial Advice - Just perfecting a process... At the time of this posting, I don't own any positions!
Idea:
Price Target: $2.89 - 3.13 dollars
- Bullish
Not Financial Advice - Just perfecting a process... Do you own due diligence before investing!
Leave a comment that is helpful or encouraging. Let's master the markets together
Not Financial Advice - Just perfecting a process... At the time of this posting, I don't own any positions!
Idea:
Price Target: $2.89 - 3.13 dollars
- Bullish
Not Financial Advice - Just perfecting a process... Do you own due diligence before investing!
Leave a comment that is helpful or encouraging. Let's master the markets together